Myriad Genetics
MYGN
MYGN
197 hedge funds and large institutions have $2.25B invested in Myriad Genetics in 2021 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 53 increasing their positions, 73 reducing their positions, and 25 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
3.11% less ownership
Funds ownership: 99.93% → 96.82% (-3.1%)
27% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 73
Holders
197
Holding in Top 10
2
Calls
$5.65M
Puts
$2.59M
Top Buyers
1 | +$82.8M | |
2 | +$26.8M | |
3 | +$22.2M | |
4 |
Invesco
Atlanta,
Georgia
|
+$14.6M |
5 |
EARNEST Partners
Atlanta,
Georgia
|
+$13.8M |
Top Sellers
1 | -$60.9M | |
2 | -$45M | |
3 | -$33.9M | |
4 |
D.E. Shaw & Co
New York
|
-$16.9M |
5 |
Northern Trust
Chicago,
Illinois
|
-$13.7M |